A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

Microbiol Spectr. 2023 Dec 12;11(6):e0179423. doi: 10.1128/spectrum.01794-23. Epub 2023 Oct 25.

Abstract

The essential goal of vaccination is to generate potent and long-term protection against diseases. Several factors including vaccine vector, delivery route, and boosting regimen influence the outcome of prime-boost immunization approaches. The immunization regimens by constructing a novel simian adenovirus-vectored COVID-19 vaccine and employing combination of intranasal and intramuscular inoculations could elicit mucosal neutralizing antibodies against five mutant strains in the respiratory tract and strong systemic immunity. Immune protection could last for more than 32 weeks. Vectored vaccine construction and immunization regimens have positively impacted respiratory disease prevention.

Keywords: adenoviral vector; intranasal immunization; mucosal immunity; respiratory virus; vaccination regimen.

MeSH terms

  • Adenoviridae / genetics
  • Adenoviruses, Simian*
  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Genetic Vectors
  • Humans
  • Immunity, Mucosal
  • Mice
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Antibodies, Neutralizing
  • Antibodies, Viral